Cormorant Asset Management, LP Kezar Life Sciences, Inc. Transaction History

Cormorant Asset Management, LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$4.58 - $17.13 $5.5 Million - $20.6 Million	1,200,000 New	1,200,000 $9.92 Million
Q4 2020 Feb 16, 2021	SELL	$4.77 - $6.58 $4.44 Million - $6.13 Million	-931,800 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$4.36 - $5.5 $1.61 Million - $2.03 Million	-368,200 Reduced 28.32%	931,800 $4.51 Million
Q2 2020 Aug 14, 2020	BUY	$3.6 - $7.75 $4.68 Million - $10.1 Million	1,300,000 New	1,300,000 $6.73 Million
Q4 2019 Feb 14, 2020	SELL	$2.5 - $4.26 $2.32 Million - $3.95 Million	-927,869 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$3.0 - $7.58 $121,275 - $306,421	-40,425 Reduced 4.17%	927,869 $3.04 Million
Q2 2019 Aug 14, 2019	SELL	$7.09 - $21.9 $2.35 Million - $7.26 Million	-331,706 Reduced 25.52%	968,294 $7.47 Million
Q1 2019 May 15, 2019	SELL	$16.83 - $23.75 $2.07 Million - $2.92 Million	-122,911 Reduced 8.64%	1,300,000 $23.1 Million
Q4 2018 Feb 14, 2019	SELL	$20.21 - $32.9 $2.63 Million - $4.28 Million	-130,000 Reduced 8.37%	1,422,911 $33.6 Million
Q3 2018 Nov 14, 2018	SELL	$15.5 - $21.41 $309,984 - $428,178	-19,999 Reduced 1.27%	1,552,911 $33.2 Million
Q2 2018 Aug 14, 2018	BUY	$17.15 - $17.79 $27 Million - $28 Million	1,572,910 New	1,572,910 $27.2 Million

1.54M

Ticker KZR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,369,504
Market Cap $438M
Description
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical tria...

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cormorant Asset Management, LP with notifications on news.